Stavian Chemical Climbs to Top 15 in ICIS Top 100 Global Chemical Distributors 2025
HANOI, Vietnam, June 16, 2025 /PRNewswire/ -- Stavian Chemical, a leading global…
ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
SHANGHAI, June 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
XRP News: Vaultro Finance Presale on XRP ledger Skyrockets Past 50%, As Investors Race to Own $VLT Token
SINGAPORE , June 15, 2025 (GLOBE NEWSWIRE) -- Vaultro Finance has just…
BestOnlineSportsbooks.info Publishes New Report on the Rise of Cryptocurrency in U.S. Sportsbooks
Saint John, Antigua and Barbuda, June 14, 2025 (GLOBE NEWSWIRE) -- BestOnlineSportsbooks.info,…
DNMiner Launches Revolutionary $100 Welcome Bonus on AIPowered Cloud Mining Platform
Short-term crypto mining contracts deliver daily returns with no hardware setup June…
AV-Comparatives Validates Real-World Threat Detection in 2025 EDR XDR MDR Certification Testing
INNSBRUCK, Austria, June 15, 2025 /PRNewswire/ -- "As cyberattacks evolve, detection can't…
Kia Wins Gold at PR Awards AsiaPacific 2025 for PR Communication Promoting Global Awareness of Ocean Plastic Cleanup
Kia Global PR Group wins Gold award in Environmental category at PR…
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial…
Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients](https://i1.wp.com/ml-eu.globenewswire.com/media/NTJlMDkyZjktNGMwNi00N2YyLTkyZmQtZTIwMWJlNzgxOWYyLTEwMTI2MjEtMjAyNS0wNi0xNS1lbg==/tiny/F-Hoffmann-La-Roche-Ltd.png?w=420&resize=420,280&ssl=1 "[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients")
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
After a thorough clinical review, the benefit-risk for the use of Elevidys…
